<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">CNS Drug Rev</journal-id><journal-id journal-id-type="iso-abbrev">CNS Drug Rev</journal-id><journal-id journal-id-type="pmc-domain-id">3671</journal-id><journal-id journal-id-type="pmc-domain">cnsdrugrev</journal-id><journal-id journal-id-type="publisher-id">CNS</journal-id><journal-title-group><journal-title>CNS Drug Reviews</journal-title></journal-title-group><issn pub-type="ppub">1080-563X</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6494138</article-id><article-id pub-id-type="pmcid-ver">PMC6494138.1</article-id><article-id pub-id-type="pmcaid">6494138</article-id><article-id pub-id-type="pmcaiid">6494138</article-id><article-id pub-id-type="pmid">16958984</article-id><article-id pub-id-type="doi">10.1111/j.1527-3458.2006.00100.x</article-id><article-id pub-id-type="publisher-id">CNS100</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>A&#8208;85380: A Pharmacological Probe for the Preclinical and Clinical Investigation of the &#945;<sub>4</sub>&#946;<sub>2</sub> Neuronal Nicotinic Acetylcholine Receptor</article-title></title-group><contrib-group><contrib id="cr1" contrib-type="author" corresp="yes"><name name-style="western"><surname>Rueter</surname><given-names initials="LE">Lynne E.</given-names></name><xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref></contrib><contrib id="cr2" contrib-type="author"><name name-style="western"><surname>Donnelly&#8208;Roberts</surname><given-names initials="DL">Diana L.</given-names></name><xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref></contrib><contrib id="cr3" contrib-type="author"><name name-style="western"><surname>Curzon</surname><given-names initials="P">Peter</given-names></name><xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref></contrib><contrib id="cr4" contrib-type="author"><name name-style="western"><surname>Briggs</surname><given-names initials="CA">Clark A.</given-names></name><xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref></contrib><contrib id="cr5" contrib-type="author"><name name-style="western"><surname>Anderson</surname><given-names initials="DJ">David J.</given-names></name><xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref></contrib><contrib id="cr6" contrib-type="author"><name name-style="western"><surname>Bitner</surname><given-names initials="RS">Robert S.</given-names></name><xref ref-type="aff" rid="a1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="a1">
<label><sup>1</sup></label>Abbott Laboratories, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Park, IL, USA</aff><author-notes><corresp id="correspondenceTo"><label>*</label>Address correspondence and reprint requests to Lynne Rueter, Abbott, R4N5, AP9A, 100 Abbott Park Rd., Abbott Park, IL, USA, 60064&#8208;6115; Fax: +1 (847) 938&#8208;0072; E&#8208;mail: <email>lynne.e.rueter@abbott.com</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>8</month><year>2006</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2006</year></pub-date><volume>12</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">333831</issue-id><issue-id pub-id-type="doi">10.1111/cns.2006.12.issue-2</issue-id><fpage>100</fpage><lpage>112</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>06</month><year>2006</year></date></event><event event-type="pmc-live"><date><day>16</day><month>09</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-09-17 00:23:13.350"><day>17</day><month>09</month><year>2019</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CNS-12-100.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CNS-12-100.pdf"/><abstract><title>ABSTRACT</title><p>A&#8208;85380 [3&#8208;(2(s)&#8208;azetidinylmethoxy) pyridine] is a neuronal nicotinic acetylcholine receptor (nAChR) agonist that has been a useful tool in the investigation of the function of nAChRs in both preclinical and clinical studies. Amongst nAChR subtypes, A&#8208;85380 shows selectivity for the &#945;<sub>4</sub>&#946;<sub>2</sub> vs. the &#945;<sub>7</sub> or &#945;<sub>1</sub>&#946;<sub>1</sub>&#948;&#947; nAChRs. In functional in vitro cation flux assays, A&#8208;85380 is a potent and full agonist. A&#8208;85380 has a broad&#8208;spectrum analgesic profile with efficacy in acute, persistent, and neuropathic pain models. As demonstrated using selective nAChR antagonists or &#945;<sub>4</sub> antisense, the &#945;<sub>4</sub>&#946;<sub>2</sub> nAChR mediates the analgesic effects of A&#8208;85380. Interestingly, the site of action depends upon the type of pain as antinociception is mediated by descending inhibition into the spinal cord whereas anti&#8208;allodynia in neuropathic pain is mediated at both central and peripheral sites. Radiolabelled forms of A&#8208;85380 have been developed and shown to be safe for use in vivo in humans. In clinical studies using positron and photon emission tomography, marked decreases in &#945;<sub>4</sub>&#946;<sub>2</sub> nAChRs have been seen in patients with Parkinson's and Alzheimer's disease. Although not developed as a therapeutic agent, A&#8208;85380 has proven to be an important component in the development of novel nAChR ligands for the treatment of pain and other disorders.</p></abstract><kwd-group><kwd id="k1">A&#8208;85380</kwd><kwd id="k2">Alzheimer's disease</kwd><kwd id="k3">Neuronal nicotinic acetylcholine receptor</kwd><kwd id="k4">Neuropathic pain</kwd><kwd id="k5">Parkinson's disease</kwd><kwd id="k6">Radioligands</kwd><kwd id="k7">Smoking</kwd></kwd-group><counts><ref-count count="62"/><page-count count="13"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>June 2006</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.2.1 mode:remove_FC converted:03.05.2019</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>